Legal status in the United States

Is Survodutide legal?

Read at FDA, DEA and WADAPublished by PepVault

Survodutide has no FDA-approved product (it is in phase 3 trials), is not a federally controlled substance, and is not named on WADA’s Prohibited List (from January 1, 2027, its S0 class names peptides in general), as of November 18, 2026.

Survodutide at a glance

CheckStatus, read Nov 18, 2026
FDA approvalNot approved; in phase 3 trials
CompoundingNot named on FDA’s lists
DEA scheduleNot controlled
Sport (WADA)Not named; from 2027, S0 names peptides in general

FDA approval

Survodutide has no FDA-approved product: Drugs@FDA lists no application for it. FDA writes that it has warned companies that illegally sold unapproved drugs containing survodutide, among others, labeled “for research purposes”.

In clinical trials

Boehringer Ingelheim is testing it in phase 3 trials: ClinicalTrials.gov lists 6 active phase 3 studies of survodutide, among them one in the fatty-liver disease MASH with liver scarring.

A smiling man in a grey t-shirt in his living room, holding his phone

PepVault for iPhone

Keep your own record in PepVault

Log your doses and vials, with a reminder for the next one.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Compounding

FDA’s compounding lists don’t name it: not in any of the three 503A categories on FDA’s list updated May 14, 2026, not on FDA’s category 2 page, and not on the 503B bulks list.

DEA schedule

It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.

Sport (WADA)

Until December 31, 2026: The 2026 Prohibited List doesn’t name survodutide. S0 bans any substance not covered elsewhere on the list that has “no current approval by any governmental regulatory health authority for human therapeutic use”; whether that reaches it turns on its approval outside the United States, which this page doesn’t cover. From January 1, 2027: WADA’s 2027 list adds “peptides” to S0’s examples of non-approved substances, and its explanatory note says a peptide not named on the list “may still be prohibited”. It still doesn’t name survodutide, and whether S0 reaches it still turns on its approval outside the United States.

How it is sold when it isn’t approved

FDA has warned companies that sold unapproved GLP-1 drugs labeled “for research purposes” or “not for human consumption” to consumers with dosing instructions, and calls that label false. FDA’s page names GLP-1 drugs; a research label is not an FDA approval of any kind.

The source: falsely labeled “for research purposes” or “not for human consumption.”

What this means and doesn’t

This page reports what the agencies’ own pages said about Survodutide in the United States when we read them on November 18, 2026. These are records of regulators, not study evidence; for what the research shows, see the compound page.

It is not legal advice, and it doesn’t cover state laws or other countries, whose rules differ. Agencies change their lists, so each fact carries its date and a link to the page it came from.

Questions

  • Is Survodutide FDA approved?

    Survodutide has no FDA-approved product: Drugs@FDA lists no application for it. FDA writes that it has warned companies that illegally sold unapproved drugs containing survodutide, among others, labeled “for research purposes”. Boehringer Ingelheim is testing it in phase 3 trials: ClinicalTrials.gov lists 6 active phase 3 studies of survodutide, among them one in the fatty-liver disease MASH with liver scarring.

  • Is Survodutide a controlled substance?

    It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.

  • Is Survodutide banned in sport?

    Until December 31, 2026: The 2026 Prohibited List doesn’t name survodutide. S0 bans any substance not covered elsewhere on the list that has “no current approval by any governmental regulatory health authority for human therapeutic use”; whether that reaches it turns on its approval outside the United States, which this page doesn’t cover. From January 1, 2027: WADA’s 2027 list adds “peptides” to S0’s examples of non-approved substances, and its explanatory note says a peptide not named on the list “may still be prohibited”. It still doesn’t name survodutide, and whether S0 reaches it still turns on its approval outside the United States.

  • What does FDA say about compounding Survodutide?

    FDA’s compounding lists don’t name it: not in any of the three 503A categories on FDA’s list updated May 14, 2026, not on FDA’s category 2 page, and not on the 503B bulks list.

  • What does FDA say about the “research use only” label?

    FDA has warned companies that sold unapproved GLP-1 drugs labeled “for research purposes” or “not for human consumption” to consumers with dosing instructions, and calls that label false. FDA’s page names GLP-1 drugs; a research label is not an FDA approval of any kind.

Read next

Track it in the app

PepVault for iPhone

Keep your own record in PepVault

Log your doses and vials, with a reminder for the next one.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo